Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.43
NAS:QGEN's Cash to Debt is ranked lower than
75% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. NAS:QGEN: 0.43 )
Ranked among companies with meaningful Cash to Debt only.
NAS:QGEN' s Cash to Debt Range Over the Past 10 Years
Min: 0.31  Med: 0.93 Max: 3.38
Current: 0.43
0.31
3.38
Equity to Asset 0.62
NAS:QGEN's Equity to Asset is ranked higher than
56% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:QGEN: 0.62 )
Ranked among companies with meaningful Equity to Asset only.
NAS:QGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.61 Max: 0.72
Current: 0.62
0.44
0.72
Interest Coverage 3.85
NAS:QGEN's Interest Coverage is ranked lower than
85% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NAS:QGEN: 3.85 )
Ranked among companies with meaningful Interest Coverage only.
NAS:QGEN' s Interest Coverage Range Over the Past 10 Years
Min: 2.05  Med: 4.4 Max: 8.44
Current: 3.85
2.05
8.44
F-Score: 7
Z-Score: 3.15
M-Score: -2.63
WACC vs ROIC
7.09%
4.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.11
NAS:QGEN's Operating margin (%) is ranked higher than
73% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.98 vs. NAS:QGEN: 11.11 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:QGEN' s Operating margin (%) Range Over the Past 10 Years
Min: 4.86  Med: 13.63 Max: 21.6
Current: 11.11
4.86
21.6
Net-margin (%) 8.99
NAS:QGEN's Net-margin (%) is ranked higher than
79% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.37 vs. NAS:QGEN: 8.99 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:QGEN' s Net-margin (%) Range Over the Past 10 Years
Min: 5.31  Med: 9.95 Max: 15.14
Current: 8.99
5.31
15.14
ROE (%) 4.58
NAS:QGEN's ROE (%) is ranked higher than
60% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.20 vs. NAS:QGEN: 4.58 )
Ranked among companies with meaningful ROE (%) only.
NAS:QGEN' s ROE (%) Range Over the Past 10 Years
Min: 2.49  Med: 5.08 Max: 13.21
Current: 4.58
2.49
13.21
ROA (%) 2.84
NAS:QGEN's ROA (%) is ranked higher than
63% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.94 vs. NAS:QGEN: 2.84 )
Ranked among companies with meaningful ROA (%) only.
NAS:QGEN' s ROA (%) Range Over the Past 10 Years
Min: 1.65  Med: 3.2 Max: 6.83
Current: 2.84
1.65
6.83
ROC (Joel Greenblatt) (%) 21.46
NAS:QGEN's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 215 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -11.88 vs. NAS:QGEN: 21.46 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:QGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 10.11  Med: 28.13 Max: 45.64
Current: 21.46
10.11
45.64
Revenue Growth (3Y)(%) 7.70
NAS:QGEN's Revenue Growth (3Y)(%) is ranked higher than
68% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.50 vs. NAS:QGEN: 7.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:QGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.1  Med: 7.7 Max: 44.5
Current: 7.7
-2.1
44.5
EBITDA Growth (3Y)(%) 6.40
NAS:QGEN's EBITDA Growth (3Y)(%) is ranked higher than
62% of the 128 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NAS:QGEN: 6.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:QGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.3  Med: 10.6 Max: 49.7
Current: 6.4
-9.3
49.7
EPS Growth (3Y)(%) 6.40
NAS:QGEN's EPS Growth (3Y)(%) is ranked higher than
61% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.00 vs. NAS:QGEN: 6.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:QGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -22.5  Med: 8.6 Max: 47.4
Current: 6.4
-22.5
47.4
» NAS:QGEN's 10-Y Financials

Financials (Next Earnings Date: Est. 2017-02-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

QGEN Guru Trades in Q4 2015

Oakmark Intl Small Cap 188,000 sh (New)
Jim Simons 210,223 sh (New)
Manning & Napier Advisors, Inc 2,857,499 sh (+5.05%)
PRIMECAP Management 20,532,325 sh (-6.06%)
» More
Q1 2016

QGEN Guru Trades in Q1 2016

George Soros 78,400 sh (New)
Oakmark Intl Small Cap 1,451,000 sh (+671.81%)
Manning & Napier Advisors, Inc 4,641,049 sh (+62.42%)
PRIMECAP Management 20,493,375 sh (-0.19%)
Jim Simons 174,597 sh (-16.95%)
» More
Q2 2016

QGEN Guru Trades in Q2 2016

Paul Tudor Jones 16,200 sh (New)
Oakmark Intl Small Cap 2,323,000 sh (+60.10%)
Manning & Napier Advisors, Inc 6,111,364 sh (+31.68%)
Jim Simons Sold Out
George Soros Sold Out
PRIMECAP Management 20,128,325 sh (-1.78%)
» More
Q3 2016

QGEN Guru Trades in Q3 2016

Steven Cohen 294,400 sh (New)
Jim Simons 190,000 sh (New)
Paul Tudor Jones 17,000 sh (+4.94%)
PRIMECAP Management 19,473,847 sh (-3.25%)
Manning & Napier Advisors, Inc 5,295,154 sh (-13.36%)
Oakmark Intl Small Cap 1,666,000 sh (-28.28%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414 
Compare:NAS:DXCM, OTCPK:BMXMF, NYSE:PKI, OTCPK:ERFSF, NYSE:BIO.B, NAS:ICLR, NAS:CPHD, NAS:BRKR, NAS:VWR, NYSE:CRL, NYSE:ALR, NAS:PRAH, NAS:PRXL, NAS:INCR, OTCPK:CZMWY, NAS:NEOG, NAS:IDXX, NAS:EXAS, NAS:MEDP, NAS:AXDX » details
Traded in other countries:QIA.Germany, QIA.Switzerland, 0H1Z.UK,
Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.

Qiagen NV provides Sample & Assay Technologies, based on market studies of United States and European market shares for its products and technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics. The Company markets more than 500 core products that are distributed in thousands of variations and combinations. In October 2012, the company announced a collaboration with Bayer HealthCare for development and commercialization of companion diagnostics paired with novel Bayer drugs, initially to enhance the treatment of various solid tumors. The Company has developed and advanced a broad range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue. It has also developed assays that enable the analysis of various kinds of molecules from virtually any biological sample. Assay technologies make information contained in isolated molecules visible and available for interpretation. The Company sells varied and flexible workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases. The Company markets its products in more than 100 countries throughout the world. The Company's competitors includes Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for protein fractionation products. The Company is subject to a variety of laws and regulations in the European Union, the United States and other countries.

Ratios

vs
industry
vs
history
P/E(ttm) 60.16
QGEN's P/E(ttm) is ranked lower than
85% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. QGEN: 60.16 )
Ranked among companies with meaningful P/E(ttm) only.
QGEN' s P/E(ttm) Range Over the Past 10 Years
Min: 23.37  Med: 40.02 Max: 147.75
Current: 60.16
23.37
147.75
Forward P/E 22.83
QGEN's Forward P/E is ranked lower than
55% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.19 vs. QGEN: 22.83 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 61.58
QGEN's PE(NRI) is ranked lower than
85% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. QGEN: 61.58 )
Ranked among companies with meaningful PE(NRI) only.
QGEN' s PE(NRI) Range Over the Past 10 Years
Min: 23.37  Med: 40.12 Max: 147.75
Current: 61.58
23.37
147.75
Price/Owner Earnings (ttm) 35.45
QGEN's Price/Owner Earnings (ttm) is ranked lower than
61% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.10 vs. QGEN: 35.45 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
QGEN' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 15.26  Med: 37.79 Max: 269.81
Current: 35.45
15.26
269.81
P/B 2.63
QGEN's P/B is ranked higher than
66% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.41 vs. QGEN: 2.63 )
Ranked among companies with meaningful P/B only.
QGEN' s P/B Range Over the Past 10 Years
Min: 1.2  Med: 2.19 Max: 4.82
Current: 2.63
1.2
4.82
P/S 5.43
QGEN's P/S is ranked lower than
68% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. QGEN: 5.43 )
Ranked among companies with meaningful P/S only.
QGEN' s P/S Range Over the Past 10 Years
Min: 2.8  Med: 4.34 Max: 6.03
Current: 5.43
2.8
6.03
PFCF 31.77
QGEN's PFCF is ranked lower than
60% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.06 vs. QGEN: 31.77 )
Ranked among companies with meaningful PFCF only.
QGEN' s PFCF Range Over the Past 10 Years
Min: 19.2  Med: 33.84 Max: 156.67
Current: 31.77
19.2
156.67
POCF 21.77
QGEN's POCF is ranked lower than
60% of the 82 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.55 vs. QGEN: 21.77 )
Ranked among companies with meaningful POCF only.
QGEN' s POCF Range Over the Past 10 Years
Min: 11.73  Med: 20.52 Max: 51.85
Current: 21.77
11.73
51.85
EV-to-EBIT 50.17
QGEN's EV-to-EBIT is ranked lower than
85% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.61 vs. QGEN: 50.17 )
Ranked among companies with meaningful EV-to-EBIT only.
QGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 16.7  Med: 33.5 Max: 93
Current: 50.17
16.7
93
EV-to-EBITDA 21.25
QGEN's EV-to-EBITDA is ranked lower than
60% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.28 vs. QGEN: 21.25 )
Ranked among companies with meaningful EV-to-EBITDA only.
QGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.4  Med: 16.5 Max: 29.1
Current: 21.25
9.4
29.1
PEG 11.35
QGEN's PEG is ranked lower than
86% of the 37 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.64 vs. QGEN: 11.35 )
Ranked among companies with meaningful PEG only.
QGEN' s PEG Range Over the Past 10 Years
Min: 2.29  Med: 5.23 Max: 1128.64
Current: 11.35
2.29
1128.64
Shiller P/E 69.22
QGEN's Shiller P/E is ranked lower than
79% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 37.25 vs. QGEN: 69.22 )
Ranked among companies with meaningful Shiller P/E only.
QGEN' s Shiller P/E Range Over the Past 10 Years
Min: 27.06  Med: 47.81 Max: 69.89
Current: 69.22
27.06
69.89
Current Ratio 3.85
QGEN's Current Ratio is ranked higher than
68% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. QGEN: 3.85 )
Ranked among companies with meaningful Current Ratio only.
QGEN' s Current Ratio Range Over the Past 10 Years
Min: 1.45  Med: 3.19 Max: 6.29
Current: 3.85
1.45
6.29
Quick Ratio 3.27
QGEN's Quick Ratio is ranked higher than
67% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.17 vs. QGEN: 3.27 )
Ranked among companies with meaningful Quick Ratio only.
QGEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 2.6 Max: 5.75
Current: 3.27
1.18
5.75
Days Inventory 106.79
QGEN's Days Inventory is ranked lower than
55% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 89.17 vs. QGEN: 106.79 )
Ranked among companies with meaningful Days Inventory only.
QGEN' s Days Inventory Range Over the Past 10 Years
Min: 94.1  Med: 115.94 Max: 160.09
Current: 106.79
94.1
160.09
Days Sales Outstanding 71.23
QGEN's Days Sales Outstanding is ranked lower than
59% of the 167 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.99 vs. QGEN: 71.23 )
Ranked among companies with meaningful Days Sales Outstanding only.
QGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.03  Med: 72 Max: 78.03
Current: 71.23
63.03
78.03
Days Payable 30.77
QGEN's Days Payable is ranked lower than
76% of the 157 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 59.52 vs. QGEN: 30.77 )
Ranked among companies with meaningful Days Payable only.
QGEN' s Days Payable Range Over the Past 10 Years
Min: 30.77  Med: 46.77 Max: 68.16
Current: 30.77
30.77
68.16

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 0.20
QGEN's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.50 vs. QGEN: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
QGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -15.6  Med: -1.1 Max: 0.3
Current: 0.2
-15.6
0.3

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 88.78
QGEN's Price/Tangible Book is ranked lower than
99% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.64 vs. QGEN: 88.78 )
Ranked among companies with meaningful Price/Tangible Book only.
QGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.91  Med: 13.1 Max: 22040
Current: 88.78
2.91
22040
Price/Projected FCF 1.81
QGEN's Price/Projected FCF is ranked higher than
55% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.97 vs. QGEN: 1.81 )
Ranked among companies with meaningful Price/Projected FCF only.
QGEN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.04  Med: 1.85 Max: 30.77
Current: 1.81
1.04
30.77
Price/DCF (Earnings Based) 5.66
QGEN's Price/DCF (Earnings Based) is ranked lower than
100% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.02 vs. QGEN: 5.66 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.23
QGEN's Price/Median PS Value is ranked lower than
63% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.03 vs. QGEN: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
QGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.49  Med: 1.05 Max: 8.45
Current: 1.23
0.49
8.45
Price/Peter Lynch Fair Value 7.07
QGEN's Price/Peter Lynch Fair Value is ranked lower than
91% of the 23 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.88 vs. QGEN: 7.07 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
QGEN' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.74  Med: 3.72 Max: 8.69
Current: 7.07
0.74
8.69
Price/Graham Number 15.36
QGEN's Price/Graham Number is ranked lower than
100% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.92 vs. QGEN: 15.36 )
Ranked among companies with meaningful Price/Graham Number only.
QGEN' s Price/Graham Number Range Over the Past 10 Years
Min: 1.55  Med: 5.28 Max: 244.89
Current: 15.36
1.55
244.89
Earnings Yield (Greenblatt) (%) 2.01
QGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. QGEN: 2.01 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
QGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.1  Med: 3 Max: 6
Current: 2.01
1.1
6
Forward Rate of Return (Yacktman) (%) 10.79
QGEN's Forward Rate of Return (Yacktman) (%) is ranked higher than
54% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.71 vs. QGEN: 10.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
QGEN' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.8  Med: 9.7 Max: 13.4
Current: 10.79
-1.8
13.4

More Statistics

Revenue (TTM) (Mil) $1,320
EPS (TTM) $ 0.49
Beta1.10
Short Percentage of Float1.94%
52-Week Range $19.94 - 28.77
Shares Outstanding (Mil)234.25

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,348 1,439 1,513
EPS ($) 1.09 1.24 1.38
EPS w/o NRI ($) 1.09 1.24 1.38
EPS Growth Rate
(3Y to 5Y Estimate)
9.03%
Dividends Per Share ($)
» More Articles for QGEN

Headlines

Articles On GuruFocus.com
David Herro's Oakmark International Small Cap Fund 4th Quarter Commentary Jan 08 2016 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 

More From Other Websites
Qiagen NV (QGEN) Hedge Funds Are Snapping Up Dec 07 2016
QIAGEN launches unique CALR mutation assay for MPN diagnosis Dec 01 2016
QIAGEN and CosmosID launch new plugin for metagenomics analysis Nov 23 2016
QIAGEN and CosmosID Launch New Plugin for Metagenomics Analysis Nov 22 2016
HTG Molecular Diagnostics and QIAGEN Team Up to Advance Precision Diagnostics Nov 16 2016
HTG Molecular Diagnostics and QIAGEN Team Up to Advance Precision Diagnostics Nov 16 2016
ETFs with exposure to QIAGEN NV : November 14, 2016 Nov 14 2016
QIAGEN NV :QGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016 Nov 10 2016
QIAGEN GeneReader NGS System to relaunch in U.S. market Nov 09 2016
QIAGEN GeneReader NGS System to Relaunch in U.S. Market Nov 09 2016
QIAGEN's GeneReader NGS System Streamlines Data Management for Labs Nov 09 2016
QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : November 7, 2016 Nov 07 2016
Qiagen (QGEN) Tops Q3 Earnings & Sales, Provides '17 View Nov 03 2016
Qiagen upgraded by BofA/Merrill Nov 03 2016
Edited Transcript of QGEN earnings conference call or presentation 2-Nov-16 9:00pm GMT Nov 02 2016
Qiagen beats Street 3Q forecasts Nov 02 2016
Qiagen beats Street 3Q forecasts Nov 02 2016
QIAGEN launches restructuring initiatives, revises outlook for 2016 earnings and provides initial... Nov 02 2016
QIAGEN reports results for third quarter and first nine months of 2016 Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)